$BTCS
BTCS Inc. Stock $btcs

$btcs Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016688 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$385.8K	$311.5K	$563.0K
YoY Change	-25.0%	-44.67%	676.37%
Cost Of Revenue	$113.6K	$82.01K	$137.9K
YoY Change	20.99%	-40.51%	819.13%
Gross Profit	$272.1K	$229.5K	$425.2K
YoY Change	-35.27%	-46.02%	639.13%
Gross Profit Margin	70.55%	73.67%	75.51%
Selling, General & Admin	$620.3K	$616.1K	$2.116M
YoY Change	15.78%	-70.88%	-73.19%
% of Gross Profit	227.93%	268.45%	497.7%
Research & Development	$180.9K	$201.6K	$136.7K
YoY Change	-2.22%	47.47%	64.86%
% of Gross Profit	66.47%	87.86%	32.16%
Depreciation & Amortization	$1.170K	$1.153K	$800.00
YoY Change	25.81%	44.13%	280.95%
% of Gross Profit	0.43%	0.5%	0.19%
Operating Expenses	$1.433M	$1.358M	$2.253M
YoY Change	-85.46%	-39.72%	-71.76%
Operating Profit	-$1.161M	-$1.128M	-$1.828M
YoY Change	-87.69%	-38.26%	-76.92%
Interest Expense	$731.2K	-$268.2K	-$570.1K
YoY Change	-65.32%	-52.96%	-123.38%
% of Operating Profit
Other Income/Expense, Net	$142.5K	-$285.0K	-$35.63K
YoY Change	-91.67%	699.89%	-97.26%
Pretax Income	-$1.018M	-$1.413M	-$5.741M
YoY Change	-86.82%	-75.38%	-15.36%
Income Tax
% Of Pretax Income
Net Earnings	-$1.018M	-$1.413M	-$5.741M
YoY Change	-86.82%	-75.38%	-15.36%
Net Earnings / Revenue	-264.02%	-453.72%	-1019.63%
Basic Earnings Per Share	-$0.07	-$0.10	-$0.47
Diluted Earnings Per Share	-$0.07	-$0.10	-$468.8K
COMMON SHARES
Basic Shares Outstanding	13.83M shares	13.77M shares	12.25M shares
Diluted Shares Outstanding	13.87M shares	17.19M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.043M	$1.543M	$4.863M
YoY Change	-67.51%	-68.27%	-38.71%
Cash & Equivalents	$900.0K	$1.400M	$2.245M
Short-Term Investments	$100.0K	$100.0K
Other Short-Term Assets	$8.361M	$7.949M	$6.917M
YoY Change	205.49%	14.92%	1426.04%
Inventory
Prepaid Expenses	$175.4K	$93.45K
Receivables
Other Receivables
Total Short-Term Assets	$9.405M	$9.492M	$11.78M
YoY Change	58.11%	-19.42%	40.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.834K	$9.999K	$11.54K
YoY Change	-16.78%	-13.35%	57600.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$8.684M
YoY Change	-100.0%	-100.0%	12.27%
Total Long-Term Assets	$8.834K	$9.999K	$8.696M
YoY Change	-99.84%	-99.89%	12.42%
TOTAL ASSETS
Total Short-Term Assets	$9.405M	$9.492M	$11.78M
Total Long-Term Assets	$8.834K	$9.999K	$8.696M
Total Assets	$9.414M	$9.502M	$20.48M
YoY Change	-17.84%	-53.59%	26.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$188.1K	$41.95K	$102.4K
YoY Change	35.08%	-59.03%	49.34%
Accrued Expenses	$442.1K	$45.38K	$3.210K
YoY Change	56.11%	1313.8%	114.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$798.4K	$544.1K	$2.944M
YoY Change	-25.17%	-81.52%	285.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$798.4K	$544.1K	$2.944M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$798.4K	$544.1K	$2.944M
YoY Change	-25.17%	-81.52%	285.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$153.9M	-$152.9M
YoY Change	3.26%
Common Stock	$160.0M	$161.9M
YoY Change	0.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.615M	$8.958M	$17.53M
YoY Change
Total Liabilities & Shareholders Equity	$9.414M	$9.502M	$20.48M
YoY Change	-17.84%	-53.59%	26.99%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.018M	-$1.413M	-$5.741M
YoY Change	-86.82%	-75.38%	-15.36%
Depreciation, Depletion And Amortization	$1.170K	$1.153K	$800.00
YoY Change	25.81%	44.13%	280.95%
Cash From Operating Activities	-$919.5K	-$1.126M	-$1.055M
YoY Change	-153.89%	6.71%	-58.48%
INVESTING ACTIVITIES
Capital Expenditures	$1.670M		-$8.524M
YoY Change	-369.36%
Acquisitions
YoY Change
Other Investing Activities	$1.672M	$47.54K	$310.2K
YoY Change		-84.67%
Cash From Investing Activities	$2.140K	-$86.48K	-$8.214M
YoY Change	-100.35%	-98.95%	2.74%
FINANCING ACTIVITIES
Cash Dividend Paid		$0.00	$635.0K
YoY Change		-100.0%
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	417.7K	$508.8K	10.11M
YoY Change	-398.52%	-94.97%	-24.41%
NET CHANGE
Cash From Operating Activities	-919.5K	-$1.126M	-1.055M
Cash From Investing Activities	2.140K	-$86.48K	-8.214M
Cash From Financing Activities	417.7K	$508.8K	10.11M
Net Change In Cash	-499.6K	-$703.7K	844.2K
YoY Change	-152.79%	-183.36%	-70.31%
FREE CASH FLOW
Cash From Operating Activities	-$919.5K	-$1.126M	-$1.055M
Capital Expenditures	$1.670M		-$8.524M
Free Cash Flow	-$2.590M	-$1.126M	$7.469M
YoY Change	-211.32%	-115.08%	-393.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001436229
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	BTCS	Staked Digital Assets Currencies Non Current StakedDigitalAssetsCurrenciesNonCurrent		usd
CY2023Q1	BTCS	Distributions To Warrant Holders DistributionsToWarrantHolders		usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther		usd
CY2023Q1	BTCS	Blockchain Network Fees BlockchainNetworkFees		usd
CY2023Q1	BTCS	Increase Decrease In Capital Shares Payable IncreaseDecreaseInCapitalSharesPayable		usd
CY2023Q1	BTCS	Increase Decrease In Dividends Payable IncreaseDecreaseInDividendsPayable		usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock		usd
CY2023Q1	BTCS	Dividends Payable DividendsPayable		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40792
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BTCS Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-1096644
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9466 Georgia Avenue #124
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Silver Spring
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20910
CY2023Q1	dei	City Area Code CityAreaCode	202
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	430-6576
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2023Q1	dei	Trading Symbol TradingSymbol	BTCS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13830303	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1443058	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2146783	usd
CY2023Q1	BTCS	Crypto Assetscurrencies CryptoAssetscurrencies	1066	usd
CY2022Q4	BTCS	Crypto Assetscurrencies CryptoAssetscurrencies	982	usd
CY2023Q1	us-gaap	Investments And Cash InvestmentsAndCash	100000	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	100000	usd
CY2023Q1	us-gaap	Investments Investments	100000	usd
CY2022Q4	us-gaap	Investments Investments	100000	usd
CY2023Q1	BTCS	Staked Crypto Assets Currencies StakedCryptoAssetsCurrencies	7854755	usd
CY2022Q4	BTCS	Staked Crypto Assets Currencies StakedCryptoAssetsCurrencies	1826307	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	93449	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	123727	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	9492328	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4197799	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9999	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11152	usd
CY2022Q4	BTCS	Staked Digital Assets Currencies Non Current StakedDigitalAssetsCurrenciesNonCurrent	5708624	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	9999	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	5719776	usd
CY2023Q1	us-gaap	Assets Assets	9502327	usd
CY2022Q4	us-gaap	Assets Assets	9917575	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	41954	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	76727	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3429	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	295935	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	498750	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	213750	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	544133	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	586412	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	97500000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	97500000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13799745	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13799745	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13107149	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13107149	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	13800	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	13108	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	161839971	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	160800263	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152895577	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151482208	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8958194	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9331163	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9502327	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9917575	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	311508	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	563015	usd
CY2023Q1	us-gaap	Revenues Revenues	311508	usd
CY2022Q1	us-gaap	Revenues Revenues	563015	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	82014	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	137869	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	229494	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	425146	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	609829	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	650289	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	201625	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	136718	usd
CY2023Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	462090	usd
CY2022Q1	us-gaap	Compensation Expense Excluding Cost Of Good And Service Sold CompensationExpenseExcludingCostOfGoodAndServiceSold	1423896	usd
CY2023Q1	us-gaap	Marketing Expense MarketingExpense	6243	usd
CY2022Q1	us-gaap	Marketing Expense MarketingExpense	41793	usd
CY2023Q1	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	94907	usd
CY2022Q1	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3307428	usd
CY2023Q1	BTCS	Realized Gains On Crypto Asset Currency Transactions RealizedGainsOnCryptoAssetCurrencyTransactions	16831	usd
CY2022Q1	BTCS	Realized Gains On Crypto Asset Currency Transactions RealizedGainsOnCryptoAssetCurrencyTransactions	71110	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1357863	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	5489014	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	285000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	641250	usd
CY2022Q1	BTCS	Distributions To Warrant Holders DistributionsToWarrantHolders	35625	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-285000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-676875	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1413369	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5740743	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13673126	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12245278	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9331163	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	508783	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	531617	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1413369	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8958194	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12103443	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12103443	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10513767	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1289274	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-634557	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5740743	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	17531184	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	17531184	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1413369	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5740743	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1153	usd
CY2022Q1	us-gaap	Depreciation Depreciation	797	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	531617	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1289274	usd
CY2023Q1	BTCS	Validator Revenue ValidatorRevenue	311508	usd
CY2022Q1	BTCS	Validator Revenue ValidatorRevenue	563015	usd
CY2022Q1	BTCS	Blockchain Network Fees BlockchainNetworkFees	1321	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	285000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	641250	usd
CY2023Q1	BTCS	Realized Gains On Crypto Asset Currency Transactions RealizedGainsOnCryptoAssetCurrencyTransactions	16831	usd
CY2022Q1	BTCS	Realized Gains On Crypto Asset Currency Transactions RealizedGainsOnCryptoAssetCurrencyTransactions	71110	usd
CY2023Q1	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	94907	usd
CY2022Q1	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3307428	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30278	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9382	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-34773	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-36329	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-292506	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-4125	usd
CY2022Q1	BTCS	Increase Decrease In Capital Shares Payable IncreaseDecreaseInCapitalSharesPayable	75002	usd
CY2022Q1	BTCS	Increase Decrease In Dividends Payable IncreaseDecreaseInDividendsPayable	35625	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1126032	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1055243	usd
CY2023Q1	BTCS	Purchase Of Productive Crypto Assets Currencies For Validating PurchaseOfProductiveCryptoAssetsCurrenciesForValidating	134019	usd
CY2022Q1	BTCS	Purchase Of Productive Crypto Assets Currencies For Validating PurchaseOfProductiveCryptoAssetsCurrenciesForValidating	8521726	usd
CY2023Q1	BTCS	Sale Of Productive Crypto Assets Currencies SaleOfProductiveCryptoAssetsCurrencies	47543	usd
CY2022Q1	BTCS	Sale Of Productive Crypto Assets Currencies SaleOfProductiveCryptoAssetsCurrencies	310149	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2558	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86476	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8214135	usd
CY2022Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	400194	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	508783	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10513767	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	508783	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10113573	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-703725	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	844195	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2146783	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1400867	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1443058	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2245062	usd
CY2022Q1	BTCS	Dividends Payable DividendsPayable	230606	usd
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse split
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	97500000	shares
CY2023Q1	BTCS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGrantsInPeriod	P4Y9M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1170000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.12
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14600	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zwu0IixOhwL1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zlA1QCqr1GN7">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified in order to conform with the current period presentation. These reclassifications have no impact on the Company’s previously reported net income (loss).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zKSrZSGHA7h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zwFP90fZjAL2">Concentration of Cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances at four financial institutions in checking accounts and money market accounts. The Company considers all highly liquid investments with original maturities of six months or less when purchased to be cash and cash equivalents. As of March 31, 2023 and December 31, 2022, the Company had approximately $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20230331_zBdp91ohbaLi" title="Cash and cash equivalents">1.4</span> million and $<span id="xdx_90D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zHM9TVuyWvO3" title="Cash and cash equivalents">2.1</span> million in cash. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20230331__srt--RangeAxis__srt--MaximumMember_zeUyOXLQYvUd" title="Cash, FDIC insured amount">250,000</span>. As of March 31, 2023 and December 31, 2022, the Company had approximately $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_c20230331_zBSpDRYjDRRf" title="Cash, FDIC insured amount">0.7</span> million and $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_c20221231_zyKSbbNl3O34" title="Cash, FDIC insured amount">1.7</span> million in excess of the FDIC insured limit, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1400000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2100000	usd
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	700000	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	1700000	usd
CY2023Q1	us-gaap	Impairment Losses Related To Real Estate Partnerships ImpairmentLossesRelatedToRealEstatePartnerships	95000	usd
CY2022Q1	us-gaap	Impairment Losses Related To Real Estate Partnerships ImpairmentLossesRelatedToRealEstatePartnerships	3300000	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	17000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	71000	usd
CY2023Q1	BTCS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1135000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.16
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y
CY2023Q1	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	1521296	shares
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zj6qQPJRr0kd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_ztqNNHJ072Ub">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in conformity with U.S. GAAP. This requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the period. The Company’s significant estimates and assumptions include the recoverability and useful lives of indefinite life intangible assets, stock-based compensation, and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the indefinite life intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement.
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	0	usd
CY2022Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	635000	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	6000	usd
CY2022Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	42000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3513899	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3865878	shares
CY2023Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	100000	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	498750	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	100000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	213750	usd
CY2023Q1	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	The Series V: (i) is non-convertible, (ii) has a 20% liquidation preference over the shares of common stock, (iii) is non-voting and (iv) has certain rights to dividends and distributions (at the discretion of the Board of Directors)
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1150000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.15
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.63
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	14600
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	3.81
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	8.07
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9730	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0372	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0410	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0132	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1590552	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.34
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	50000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.63
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	9153	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.37
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1631399	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.25
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	286553	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1387732	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3429	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	295935	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	41954	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	76727	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45383	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	372662	usd
CY2023Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	284000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1	pure
CY2023Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	95000	usd
CY2022Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	45000	usd

Files In Submission

Name	View Source	Status
0001493152-23-016688-index-headers.html	Edgar Link	pending
0001493152-23-016688-index.html	Edgar Link	pending
0001493152-23-016688.txt	Edgar Link	pending
0001493152-23-016688-xbrl.zip	Edgar Link	pending
btcs-20230331.xsd	Edgar Link	pending
btcs-20230331_cal.xml	Edgar Link	unprocessable
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
btcs-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
btcs-20230331_lab.xml	Edgar Link	unprocessable
btcs-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTCS
BTCS Inc. Stock $btcs

2023 Q2 Form 10-Q Financial Statement

#000149315223016688 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCS BTCS Inc. Stock $btcs

2023 Q2 Form 10-Q Financial Statement

#000149315223016688 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTCS
BTCS Inc. Stock $btcs